Celin Tompkins

Statistics

Publications

Citations

H-Index

Active since

2011

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Novartis Institutes for BioMedical Research

Novartis (Switzerland)

Celin Tompkins is an author at Genomics Institute of the Novartis Research Foundation specializing in targeted cancer therapy, pharmacology, and molecular oncology.

Publications per year

2011–2016

Publications

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Jun Liu, Shifeng Pan, Mindy H. Hsieh et al. · Proceedings of the National Academy of Sciences · 2013 · 835 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Yong Jia, Jose Juarez, Jie Li et al. · Cancer Research · 2016 · 121 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors

Cheng Dai, Jun Liu, Dong Han et al. · ACS Medicinal Chemistry Letters · 2016 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Abstract B232: Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models.

Nanxin Li, Pierre‐Yves Michellys, Sung Joon Kim et al. · Molecular Cancer Therapeutics · 2011 · 18 citations

Medicine, Oncology, Pharmacology +13

Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC

Shailaja Kasibhatla, Jie Li, Celin Tompkins et al. · Cancer Research · 2014 · 10 citations

Medicine, Oncology, Pharmacology +16

1–5 of 5